FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3157090373> ?p ?o ?g. }

• W3157090373 endingPage "361" @default.
• W3157090373 startingPage "354" @default.
• W3157090373 abstract "Immunotherapy with CTLA-4 inhibitors and PD1 checkpoint inhibitors has initiated a breakthrough in the treatment and prognosis of patients with metastatic melanoma. The survival of these patients has increased from the expected survival time of less than 12 months to at least forty months. However, immunotherapy with either anti-CTLA-4 antibodies or PD1 inhibitors alone or in combination has a broad palette of significant immune-related adverse events. The aim of the study was to assess the correlation of immune-related adverse events with treatment outcomes defined as significant differences in the overall response rate (ORR) and progression-free survival (PFS) of patients, who developed immune-related adverse events during immunotherapy.A retrospective analysis of patients with metastatic melanoma treated with immunotherapy in 2020 at the Oncology Institute of Ljubljana was performed. Only patients with radiological evaluation of the immunotherapy response were included. The patients were divided into two cohorts: a cohort of patients with immune-related adverse events (irAE group) and a cohort of patients with no immune-related adverse events (NirAE group). Significantly better overall response and progression-free survival in the irAE cohort defined the primary aim of our study. To investigate the differences in progression-free survival between the irAE cohort and NirAE cohort, we used survival analysis. In particular, a Cox proportional hazards model with covariates of time to progression and adverse events was used for survival analysis. The Kruskal-Wallis H-test was applied, and a p-value of p <= 0.05 was considered the cut-off point for a statistically significant difference between the groups.Among the 120 patients treated with immunotherapy, radiological response evaluation was performed for 99 patients: 38 patients in the irAE cohort and 61 patients in the NirAE cohort. The ORRs for the irAE and NirAE cohorts were 57% and 37%, respectively. The PFS was significantly better for the irAE cohort (301.6 days) than for the NirAE cohort (247.29 days). The results of the survival regression analysis showed a significant increase in the survival probability from less than 60% for the NirAE cohort to almost 80% for the irAE cohort.Patients with metastatic melanoma treated with immunotherapy who developed immune-related adverse events showed better treatment outcomes with longer times to disease progression and better overall response rates than patients treated with immunotherapy who did not develop immune-related adverse events, with a significant increase in the survival probability from less than 60% for the NirAE cohort to almost 80% for the irAE cohort." @default.
• W3157090373 created "2021-05-10" @default.
• W3157090373 creator A5013032782 @default.
• W3157090373 creator A5021185083 @default.
• W3157090373 creator A5067298588 @default.
• W3157090373 creator A5082056233 @default.
• W3157090373 date "2021-05-04" @default.
• W3157090373 modified "2023-10-06" @default.
• W3157090373 title "Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes" @default.
• W3157090373 cites W2034021163 @default.
• W3157090373 cites W2074628873 @default.
• W3157090373 cites W2153942285 @default.
• W3157090373 cites W2488330279 @default.
• W3157090373 cites W2591772299 @default.
• W3157090373 cites W2794627893 @default.
• W3157090373 cites W2888298425 @default.
• W3157090373 cites W2890208257 @default.
• W3157090373 cites W2900126305 @default.
• W3157090373 cites W2913383852 @default.
• W3157090373 cites W2947771252 @default.
• W3157090373 cites W3001076836 @default.
• W3157090373 cites W3029560938 @default.
• W3157090373 cites W3043703771 @default.
• W3157090373 cites W3107738233 @default.
• W3157090373 cites W3114638465 @default.
• W3157090373 cites W4256631179 @default.
• W3157090373 doi "https://doi.org/10.2478/raon-2021-0019" @default.
• W3157090373 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8366732" @default.
• W3157090373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33939899" @default.
• W3157090373 hasPublicationYear "2021" @default.
• W3157090373 type Work @default.
• W3157090373 sameAs 3157090373 @default.
• W3157090373 citedByCount "5" @default.
• W3157090373 countsByYear W31570903732022 @default.
• W3157090373 countsByYear W31570903732023 @default.
• W3157090373 crossrefType "journal-article" @default.
• W3157090373 hasAuthorship W3157090373A5013032782 @default.
• W3157090373 hasAuthorship W3157090373A5021185083 @default.
• W3157090373 hasAuthorship W3157090373A5067298588 @default.
• W3157090373 hasAuthorship W3157090373A5082056233 @default.
• W3157090373 hasBestOaLocation W31570903731 @default.
• W3157090373 hasConcept C10515644 @default.
• W3157090373 hasConcept C121608353 @default.
• W3157090373 hasConcept C126322002 @default.
• W3157090373 hasConcept C143998085 @default.
• W3157090373 hasConcept C167135981 @default.
• W3157090373 hasConcept C197934379 @default.
• W3157090373 hasConcept C201903717 @default.
• W3157090373 hasConcept C203014093 @default.
• W3157090373 hasConcept C2777658100 @default.
• W3157090373 hasConcept C2777701055 @default.
• W3157090373 hasConcept C2780030458 @default.
• W3157090373 hasConcept C2780739268 @default.
• W3157090373 hasConcept C2781433595 @default.
• W3157090373 hasConcept C3019894029 @default.
• W3157090373 hasConcept C502942594 @default.
• W3157090373 hasConcept C50382708 @default.
• W3157090373 hasConcept C71924100 @default.
• W3157090373 hasConcept C72563966 @default.
• W3157090373 hasConcept C8891405 @default.
• W3157090373 hasConceptScore W3157090373C10515644 @default.
• W3157090373 hasConceptScore W3157090373C121608353 @default.
• W3157090373 hasConceptScore W3157090373C126322002 @default.
• W3157090373 hasConceptScore W3157090373C143998085 @default.
• W3157090373 hasConceptScore W3157090373C167135981 @default.
• W3157090373 hasConceptScore W3157090373C197934379 @default.
• W3157090373 hasConceptScore W3157090373C201903717 @default.
• W3157090373 hasConceptScore W3157090373C203014093 @default.
• W3157090373 hasConceptScore W3157090373C2777658100 @default.
• W3157090373 hasConceptScore W3157090373C2777701055 @default.
• W3157090373 hasConceptScore W3157090373C2780030458 @default.
• W3157090373 hasConceptScore W3157090373C2780739268 @default.
• W3157090373 hasConceptScore W3157090373C2781433595 @default.
• W3157090373 hasConceptScore W3157090373C3019894029 @default.
• W3157090373 hasConceptScore W3157090373C502942594 @default.
• W3157090373 hasConceptScore W3157090373C50382708 @default.
• W3157090373 hasConceptScore W3157090373C71924100 @default.
• W3157090373 hasConceptScore W3157090373C72563966 @default.
• W3157090373 hasConceptScore W3157090373C8891405 @default.
• W3157090373 hasIssue "3" @default.
• W3157090373 hasLocation W31570903731 @default.
• W3157090373 hasLocation W31570903732 @default.
• W3157090373 hasLocation W31570903733 @default.
• W3157090373 hasOpenAccess W3157090373 @default.
• W3157090373 hasPrimaryLocation W31570903731 @default.
• W3157090373 hasRelatedWork W2588304536 @default.
• W3157090373 hasRelatedWork W2921522183 @default.
• W3157090373 hasRelatedWork W2969738919 @default.
• W3157090373 hasRelatedWork W2981883049 @default.
• W3157090373 hasRelatedWork W3029766637 @default.
• W3157090373 hasRelatedWork W3035446385 @default.
• W3157090373 hasRelatedWork W3119950328 @default.
• W3157090373 hasRelatedWork W3135568840 @default.
• W3157090373 hasRelatedWork W3175085288 @default.
• W3157090373 hasRelatedWork W4292373623 @default.
• W3157090373 hasVolume "55" @default.
• W3157090373 isParatext "false" @default.
• W3157090373 isRetracted "false" @default.

• next